A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT ID: NCT05654623

Last Updated: 2025-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

624 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-03

Study Completion Date

2028-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to learn about the safety and effects of the study medicine ARV-471 (PF-07850327, vepdegestrant) compared to fulvestrant (FUL) in participants with advanced breast cancer. Advanced breast cancer is difficult to cure or control with treatment. The cancer may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body, i.e. bones, lungs, brain, or liver. FUL is a medicine already used for treatment of breast cancer while ARV-471 is a new medicine.

This study is seeking participants with breast cancer who:

* have cancer that has come back in the place where it started or spread to nearby tissue, lymph nodes, or distant parts of the body.
* cannot be fully cured by surgery or radiation therapy. Radiation therapy is the use of high-energy radiation such as x-rays, gamma rays and other sources to kill cancer cells and shrink tumors.
* respond to hormonal or endocrine therapy (which target hormones and/or activity of hormone receptors) such as tamoxifen or aromatase inhibitors (this is called estrogen receptor positive disease)
* have received one line of CDK4/6 inhibitor therapy (for example palbociclib, ribociclib or abemaciclib) in combination with endocrine therapy (for example letrozole) for advanced cancer.
* are allowed up to one other endocrine therapy (for example exemestane) for advanced cancer.

Half of the participants will be given ARV-471 while the other half of the participants will be given FUL.

Participants who get ARV-471 will take ARV-471 by mouth with food, one time a day. During the first treatment cycle participants who will get FUL will be given FUL by shots into the muscles on Day 1 and again 2 weeks later. After the first month, FUL shots will be given on the first day of each new treatment cycle. One treatment cycle is 28 days.

Participants will receive the study medicine until their breast cancer worsens or side effects become too severe. Participants will have visits at the study clinic about every 4 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Advanced Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ARV-471

Group Type EXPERIMENTAL

ARV-471

Intervention Type DRUG

orally, once daily on a 28-day continuous dosing schedule

Fulvestrant

Group Type ACTIVE_COMPARATOR

Fulvestrant

Intervention Type DRUG

intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ARV-471

orally, once daily on a 28-day continuous dosing schedule

Intervention Type DRUG

Fulvestrant

intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PF-07850327

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult participants with loco-regional recurrent or metastatic breast disease not amenable to surgical resection or radiation therapy
* Confirmed diagnosis of ER+/HER2- breast cancer
* Prior therapies for locoregional recurrent or metastatic disease must fulfill all the following criteria:
* One line of CDK4/6 inhibitor therapy in combination with endocrine therapy. Only one line of CDK4/6 inhibitor is allowed in any setting.
* ≤ 1 endocrine therapy in addition to CDK4/6 inhibitor with ET
* Most recent endocrine treatment duration must have been given for ≥6 months prior to disease progression. This may be the endocrine treatment component of the CDK4/6 inhibitor line of therapy.
* Radiological progression during or after the last line of therapy.
* Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease
* Eastern Cooperative Oncology Group (ECOG) performance status 0-1
* Participants should be willing to provide blood and tumor tissue

Exclusion Criteria

* Participants with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term
* Prior treatment with:
* ARV-471, fulvestrant, elacestrant, mTOR, PI3K, AKT pathway inhibitors, PARP inhibitor for any setting
* other investigational agents (including novel endocrine therapy any SERDs, SERCAs, CERANs) for any setting
* prior chemotherapy for advanced/metastatic disease
* Inadequate liver, kidney and bone marrow function
* Active brain metastases
* Participants with significant concomitant illness
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Arvinas Estrogen Receptor, Inc.

INDUSTRY

Sponsor Role collaborator

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven

Leuven, Vlaams-brabant, Belgium

Site Status

Clinical Chc Montlégia

Liège, , Belgium

Site Status

California Cancer Associates for Research and Excellence, Inc. (cCARE)

Encinitas, California, United States

Site Status

Orange Coast Memorial Medical Center

Fountain Valley, California, United States

Site Status

California Cancer Associates for Research and Excellence

Fresno, California, United States

Site Status

Providence Queen of the Valley Medical Center

Napa, California, United States

Site Status

California Cancer Associates for Research and Excellence

San Marcos, California, United States

Site Status

Olive View-UCLA Medical Center

Sylmar, California, United States

Site Status

Smilow Cancer Hospital Care Center at Fairfield

Fairfield, Connecticut, United States

Site Status

Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut, United States

Site Status

Yale-New Haven Hospital

New Haven, Connecticut, United States

Site Status

Smilow Cancer Hospital Care Center at North Haven

North Haven, Connecticut, United States

Site Status

Smilow Cancer Hospital Care Center at Trumbull

Trumbull, Connecticut, United States

Site Status

Florida Cancer Specialists

Altamonte Springs, Florida, United States

Site Status

Florida Cancer Specialists BON

Bonita Springs, Florida, United States

Site Status

Florida Cancer Specialists BCC

Bradenton, Florida, United States

Site Status

Florida Cancer Specialists LRS

Bradenton, Florida, United States

Site Status

Florida Cancer Specialists

Brandon, Florida, United States

Site Status

Florida Cancer Specialists NFM

Cape Coral, Florida, United States

Site Status

Morton Plant Hospital - BayCare Health System

Clearwater, Florida, United States

Site Status

Florida Cancer Specialists

Clearwater, Florida, United States

Site Status

Florida Cancer Specialists

Daytona Beach, Florida, United States

Site Status

Florida Cancer Specialists COL

Fort Myers, Florida, United States

Site Status

Florida Cancer Specialists GLO

Fort Myers, Florida, United States

Site Status

Florida Cancer Specialists

Gainesville, Florida, United States

Site Status

Lakeland Regional Cancer Center

Lakeland, Florida, United States

Site Status

Florida Cancer Specialists

Largo, Florida, United States

Site Status

Florida Cancer Specialists

Lecanto, Florida, United States

Site Status

Florida Cancer Specialist And Research Institute

N. Venice, Florida, United States

Site Status

Florida Cancer Specialists NGD

Naples, Florida, United States

Site Status

Florida Cnacer Specialists

North Port, Florida, United States

Site Status

Florida Cancer Specialists

Ocala, Florida, United States

Site Status

Florida Cancer Specialists

Orange City, Florida, United States

Site Status

Florida Cancer Specialists

Orlando, Florida, United States

Site Status

Florida Cancer Specialists PCH

Port Charlotte, Florida, United States

Site Status

Florida Cancer Specialists SAC

Sarasota, Florida, United States

Site Status

Florida Cancer Specialists SAD

Sarasota, Florida, United States

Site Status

Florida Cancer Specialists

St. Petersburg, Florida, United States

Site Status

Florida Cancer Specialists

Stuart, Florida, United States

Site Status

Florida Cancer Specialists

Tampa, Florida, United States

Site Status

Florida Cancer Specialists

Tavares, Florida, United States

Site Status

Florida Cancer Specialists

The Villages, Florida, United States

Site Status

Florida Cancer Specialist

Trinity, Florida, United States

Site Status

Florida Cancer Specialists

Vero Beach, Florida, United States

Site Status

Florida Cancer Specialists

Wellington, Florida, United States

Site Status

Florida Cancer Specialists

West Palm Beach, Florida, United States

Site Status

Florida Cancer Specialists

Winter Park, Florida, United States

Site Status

Hope and Healing Cancer Services

Hinsdale, Illinois, United States

Site Status

Norton Cancer Institute - Downtown

Louisville, Kentucky, United States

Site Status

Norton Cancer Institute, Downtown

Louisville, Kentucky, United States

Site Status

Norton Hospital

Louisville, Kentucky, United States

Site Status

Norton Cancer Institute, St Matthews Campus

Louisville, Kentucky, United States

Site Status

Norton Women's & Children's Hospital

Louisville, Kentucky, United States

Site Status

Norton Brownsboro Hospital

Louisville, Kentucky, United States

Site Status

Norton Cancer Institute, Brownsboro Hospital Campus

Louisville, Kentucky, United States

Site Status

University Medical Center New Orleans

New Orleans, Louisiana, United States

Site Status

Louisiana State University Health Sciences Shreveport

Shreveport, Louisiana, United States

Site Status

Hattiesburg Clinic Hematology/Oncology

Hattiesburg, Mississippi, United States

Site Status

Mercy Clinic Oncology and Hematology

Ballwin, Missouri, United States

Site Status

Saint Luke's Cancer Institute

Kansas City, Missouri, United States

Site Status

Mercy Research - David C. Pratt Cancer Center

St Louis, Missouri, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

MSK Basking Ridge

Basking Ridge, New Jersey, United States

Site Status

MSK Monmouth

Middletown, New Jersey, United States

Site Status

Memorial Sloan Kettering - Bergen

Montvale, New Jersey, United States

Site Status

Hematology Oncology Associates of CNY

Camillus, New York, United States

Site Status

MSK Commack

Commack, New York, United States

Site Status

Hematology-Oncology Associates of Central New York, PC

East Syracuse, New York, United States

Site Status

MSK Westchester

Harrison, New York, United States

Site Status

R.J. Zuckerberg Cancer Center

Lake Success, New York, United States

Site Status

Northern Westchester Hospital

Mount Kisco, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status

MSK Evelyn H. Lauder Breast and Imaging Center

New York, New York, United States

Site Status

Hematology Oncology Associates of Rockland

Nyack, New York, United States

Site Status

Phelps Hospital

Sleepy Hollow, New York, United States

Site Status

MSK Nassau

Uniondale, New York, United States

Site Status

Cancer Centers of Southwest Oklahoma

Lawton, Oklahoma, United States

Site Status

Providence Cancer Institute Franz Clinic

Portland, Oregon, United States

Site Status

Providence Portland Medical Center

Portland, Oregon, United States

Site Status

University of Virginia Cancer Center

Charlottesville, Virginia, United States

Site Status

University of Virginia Health System

Charlottesville, Virginia, United States

Site Status

UVA Breast Care Center

Charlottesville, Virginia, United States

Site Status

Bon Secours Memorial Regional Medical Center

Mechanicsville, Virginia, United States

Site Status

Bon Secours St. Francis Medical Center

Midlothian, Virginia, United States

Site Status

Bon Secours St. Mary's Hospital

Richmond, Virginia, United States

Site Status

Providence Regional Cancer System - Aberdeen

Aberdeen, Washington, United States

Site Status

Providence Regional Cancer System- Centralia

Centralia, Washington, United States

Site Status

Providence Regional Cancer System - Lacey

Lacey, Washington, United States

Site Status

UW Medicine Valley Medical Center

Renton, Washington, United States

Site Status

Centro de Oncología e Investigación de Buenos Aires

Berazategui, Buenos Aires, Argentina

Site Status

Instituto de Oncología Angel H. Roffo

CABA, Buenos Aires, Argentina

Site Status

Stat Research S.A.

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Site Status

Fundación Cenit Para La Investigación En Neurociencias

CABA, Buenos Aires F.D., Argentina

Site Status

Fundacion Estudios Clinicos

Rosario, Santa Fe Province, Argentina

Site Status

Sanatorio de La Mujer

Rosario, Santa Fe Province, Argentina

Site Status

Centro Oncologico Korben

Buenos Aires, , Argentina

Site Status

Centro de Educación Médica e Investigaciones clínicas "Dr. Norberto Quirno" (CEMIC)

Buenos Aires, , Argentina

Site Status

Fundación Respirar

Buenos Aires, , Argentina

Site Status

Clínica Universitaria Reina Fabiola

Córdoba, , Argentina

Site Status

Coffs Harbour Health Campus

Coffs Harbour, New South Wales, Australia

Site Status

Sunshine Coast University Private Hospital

Birtinya, Queensland, Australia

Site Status

Princess Alexandra Hospital

Woolloongabba, Queensland, Australia

Site Status

ICON Cancer Centre - Kurralta Park

Kurralta Park, South Australia, Australia

Site Status

Icon Cancer Centre Hobart

Hobart, Tasmania, Australia

Site Status

Cabrini Hospital -Brighton

Brighton, Victoria, Australia

Site Status

Barwon Health

Geelong, Victoria, Australia

Site Status

Cabrini Hospital - Malvern

Malvern, Victoria, Australia

Site Status

Medizinische Universität Graz

Graz, Styria, Austria

Site Status

Uniklinikum Salzburg

Salzburg, , Austria

Site Status

Antwerp University Hospital

Edegem, Antwerpen, Belgium

Site Status

Cliniques universitaires Saint-Luc

Woluwe-Saint-Lambert, Bruxelles-capitale, Région de, Belgium

Site Status

Grand Hôpital de Charleroi

Gilly, Hainaut, Belgium

Site Status

Hospital Santa Rita de Cassia

Vitória, Espírito Santo, Brazil

Site Status

ONCOSITE - Centro de Pesquisa Clinica em Oncologia

Ijuí, Rio Grande do Sul, Brazil

Site Status

Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Moinhos de Vento

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital São Lucas da PUCRS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Centro de Pesquisa Clínica - Área Administrativa

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Hospital Mae de Deus

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

ANIMI - Unidade de Tratamento Oncologico

Lages, Santa Catarina, Brazil

Site Status

Faculdade de Medicina do ABC

Santo André, São Paulo, Brazil

Site Status

A. C. Camargo Cancer Center

São Paulo, São Paulo, Brazil

Site Status

IBCC - Instituto Brasileiro de Controle do Câncer

São Paulo, , Brazil

Site Status

IBCC - Núcleo de Pesquisa e Ensino

São Paulo, , Brazil

Site Status

Complex Oncology Center - Burgas

Burgas, , Bulgaria

Site Status

Complex Oncology Center - Plovdiv EOOD

Plovdiv, , Bulgaria

Site Status

Cross Cancer Institute

Edmonton, Alberta, Canada

Site Status

BC Cancer Surrey

Surrey, British Columbia, Canada

Site Status

The Moncton Hospital

Moncton, New Brunswick, Canada

Site Status

Waterloo Regional Health Network

Kitchener, Ontario, Canada

Site Status

Sunnybrook Research Institute

Toronto, Ontario, Canada

Site Status

Unity Health Toronto, St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Centre de Services Ambulatoires de St-Jerome

Saint-Jérôme, Quebec, Canada

Site Status

Unité de Recherche Clinique du CISSS des Laurentides

Saint-Jérôme, Quebec, Canada

Site Status

Anhui Provincial Hospital

Hefei, Anhui, China

Site Status

Anhui Provincial Cancer Hospital

Hefei, Anhui, China

Site Status

Beijing Hospital

Beijing, Beijing Municipality, China

Site Status

Cancer Hospital Chinese Academy of Medical Science

Beijing, Beijing Municipality, China

Site Status

Fujian Medical University Union Hospital

Fuzhou Fujian, Fujian, China

Site Status

The First People's Hospital of Foshan

Foshan, Guangdong, China

Site Status

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Site Status

Guangxi Medical University Affiliated Tumor Hospital

Nanning, Guangxi, China

Site Status

Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, China

Site Status

The First Affiliated Hospital of Henan University of Science &Technology

Luoyang, Henan, China

Site Status

Union Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, China

Site Status

Wuhan Union Hospital Cancer Center

Wuhan, Hubei, China

Site Status

Jinyinhu Branch of Tongji Medical College Affiliated Union Hospital, Huazhong University of Science

Wuhan, Hubei, China

Site Status

Hubei Cancer Hospital

Wuhan, Hubei, China

Site Status

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing, Jiangsu, China

Site Status

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

Nanchang People's Hospital

Nanchang, Jiangxi, China

Site Status

The First Hospital of Jilin University

Changchun, Jilin, China

Site Status

The 2nd Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

Site Status

The First Hospital of China Medical University

Shenyang, Liaoning, China

Site Status

Liaoning Cancer Hospital

Shenyang, Liaoning, China

Site Status

The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Site Status

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Site Status

Shandong Cancer Hospital

Jinan, Shandong, China

Site Status

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Site Status

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Site Status

Tianjin Medical University Cancer Institute & Hospital

Tianjin, Tianjin Municipality, China

Site Status

Yunnan Province Cancer Hospital

Kunming, Yunnan, China

Site Status

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status

Zhejiang Cancer Hospital

Hangzhou, Zhejiang, China

Site Status

The Second Affiliated hospital of Zhejiang University school of medicine

Hangzhou, Zhejiang, China

Site Status

Henan Cancer Hospital

Zhengzhou, , China

Site Status

Fakultní nemocnice Brno Bohunice

Brno, Brno-město, Czechia

Site Status

Fakultni Thomayerova nemocnice

Prague, Praha 4, Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady

Prague, , Czechia

Site Status

Tampereen yliopistollinen sairaala

Tampere, Pirkanmaa, Finland

Site Status

Vaasan Keskussairaala

Vaasa, Pohjanmaa, Finland

Site Status

Satakunnan Keskussairaala

Pori, , Finland

Site Status

Centre Georges François Leclerc

Dijon, Côte-d'or, France

Site Status

Centre de Cancérologie du Grand Montpellier

Montpellier, Languedoc-roussillon, France

Site Status

Institut de Cancérologie de l'Ouest

Saint-Herblain, Loire-atlantique, France

Site Status

Institut de Cancérologie de l'Ouest

Angers, Maine-et-loire, France

Site Status

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne

Clermont-Ferrand, Puy-de-dôme, France

Site Status

Sainte Catherine Institut du Cancer Avignon Provence

Avignon, Vaucluse, France

Site Status

Centre Hospitalier Universitaire de Poitiers

Poitiers, Vienne, France

Site Status

Henri Mondor Hospital

Créteil, Île-de-France Region, France

Site Status

Onkologische Schwerpunktpraxis Kurfuerstendamm

Berlin, , Germany

Site Status

University Hospital of Patras

Pátrai, Achaḯa, Greece

Site Status

Alexandra General Hospital of Athens

Athens, Attikí, Greece

Site Status

Attikon General University Hospital

Chaidari/Athens, Attikí, Greece

Site Status

University General Hospital of Heraklion

Heraklion, Irakleío, Greece

Site Status

University General Hospital of Larissa

Larissa, Thessalía, Greece

Site Status

Petz Aladar Egyetemi Oktato Korhaz

Győr, Győr-Moson-Sopron, Hungary

Site Status

Budapesti Uzsoki Utcai Kórház

Budapest, , Hungary

Site Status

Artemis hospital

Gurgaon, Haryana, India

Site Status

Tata Memorial Hospital

Mumbai, Maharashtra, India

Site Status

HCG Manavata Cancer Centre

Nashik, Maharashtra, India

Site Status

Apex Wellness Hospital

Nashik, Maharashtra, India

Site Status

Bhakti Vedanta Hospital and Research Institute

Thāne, Maharashtra, India

Site Status

Venkateshwar Hospital

New Delhi, National Capital Territory of Delhi, India

Site Status

Rajiv Gandhi Cancer Institute And Research Centre

New Delhi, National Capital Territory of Delhi, India

Site Status

Institute of Post Graduate Medical Education and Research and Seth Sukhlal Karnani Memorial Hospital

Kolkata, West Bengal, India

Site Status

Rabin Medical Center

Petah Tikva, Central District, Israel

Site Status

Kaplan Medical Center

Rehovot, Central District, Israel

Site Status

Istituto Nazionale Tumori IRCCS Fondazione Pascale

Napoli, Campania, Italy

Site Status

Humanitas Istituto Clinico Catanese

Misterbianco, Catania, Italy

Site Status

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola

Bologna, Emilia-Romagna, Italy

Site Status

Azienda Ospedaliero Universitaria di Ferrara

Cona, Ferrara, Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore

Rome, Lazio, Italy

Site Status

Fondazione IRCCS San Gerardo dei Tintori

Monza, Lombardy, Italy

Site Status

Azienda Ospedaliero Universitaria delle Marche

Ancona, The Marches, Italy

Site Status

Azienda Ospedaliero Universitaria Pisana

Pisa, Tuscany, Italy

Site Status

Ospedale Generale Provinciale Macerata

Macerata, , Italy

Site Status

Istituto Europeo di Oncologia IRCCS

Milan, , Italy

Site Status

Istituto Oncologico Veneto IRCCS

Padua, , Italy

Site Status

Aichi Cancer Center Hospital

Nagoya, Aichi-ken, Japan

Site Status

Nagoya University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Site Status

Chiba cancer center

Chiba, Chiba, Japan

Site Status

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Site Status

National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, Japan

Site Status

Kanagawa cancer center

Yokohama, Kanagawa, Japan

Site Status

Osaka University Hospital

Suita, Osaka, Japan

Site Status

Saitama Prefectural Cancer Center

Ina-machi, Saitama, Japan

Site Status

Juntendo University Hospital

Bunkyo-ku, Tokyo, Japan

Site Status

Tokyo Metropolitan Komagome Hospital, Department of Breast Surgery

Bunkyo-ku, Tokyo, Japan

Site Status

Cancer Institute Hospital of JFCR

Koto-ku, Tokyo, Japan

Site Status

Japanese Foundation for Cancer Research

Koto, Tokyo, Japan

Site Status

National Center for Global Health and Medicine

Shinjuku, Tokyo, Japan

Site Status

Center Hospital of the National Center for Global Health and Medicine

Shinjuku-ku, Tokyo, Japan

Site Status

National Hospital Organization Kyushu Cancer Center

Fukuoka, , Japan

Site Status

Sagara Hospital

Kagoshima, , Japan

Site Status

Okayama University Hospital

Okayama, , Japan

Site Status

Boca Clinical Trials Mexico S.C.

Guadajalara, Jalisco, Mexico

Site Status

Cryptex Investigación Clínica S.A. de C.V.

Cuauhtémoc, Mexico City, Mexico

Site Status

Centro de Investigacion Clinica de Oaxaca

Oaxaca City, , Mexico

Site Status

Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.

Krakow, Lesser Poland Voivodeship, Poland

Site Status

SP ZOZ Szpital Uniwersytecki w Krakowie

Krakow, Lesser Poland Voivodeship, Poland

Site Status

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie

Warsaw, Masovian Voivodeship, Poland

Site Status

COPERNICUS PL, Wojewodzkie Centrum Onkologii

Gdansk, Pomeranian Voivodeship, Poland

Site Status

Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna

Lodz, Łódź Voivodeship, Poland

Site Status

Puerto Rico Medical Research Center

Hato Rey, Puerto RICO, Puerto Rico

Site Status

Hospital Oncológico Dr. Isaac González-Martinez

Rio Piedras, , Puerto Rico

Site Status

Pan American Center for Oncology Trials, LLC

Rio Piedras, , Puerto Rico

Site Status

FDI Clinical Research

San Juan, , Puerto Rico

Site Status

Onkologicky ustav sv. Alzbety, s.r.o.

Bratislava, , Slovakia

Site Status

Narodny onkologicky ustav

Bratislava, , Slovakia

Site Status

Vychodoslovensky onkologicky ustav, a.s.

Košice, , Slovakia

Site Status

Nemocnica na okraji mesta n o

Partizánske, , Slovakia

Site Status

Fakultna nemocnica Trnava

Trnava, , Slovakia

Site Status

Iatros International

Bloemfontein, Free State, South Africa

Site Status

Charlotte Maxeke Johannesburg Academic Hospital

Johannesburg, Gauteng, South Africa

Site Status

WCR Office

Johannesburg, Gauteng, South Africa

Site Status

Wits Clinical Research

Johannesburg, Gauteng, South Africa

Site Status

Gachon University Gil Medical Center

Namdong-gu, Incheon-gwangyeoksi [incheon], South Korea

Site Status

National Cancer Center

Goyang-si, Kyǒnggi-do, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, Kyǒnggi-do, South Korea

Site Status

Ajou University Hospital

Suwon, Kyǒnggi-do, South Korea

Site Status

Korea University Anam Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Asan Medical Center

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Gangnam Severance Hospital, Yonsei University Health System

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

Ewha Womans University Mokdong Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Site Status

CHUAC-Hospital Teresa Herrera

A Coruña, A Coruña [LA Coruña], Spain

Site Status

Hospital General Universitario de Elche

Elche, Alicante, Spain

Site Status

Institut Català d'Oncologia (ICO) - Badalona

Badalona, Barcelona [barcelona], Spain

Site Status

Parc de Salut Mar - Hospital del Mar

Barcelona, Barcelona [barcelona], Spain

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, Barcelona [barcelona], Spain

Site Status

Osi Bilbao-Basurto

Bilbao, Basque Country, Spain

Site Status

Institut Català d'Oncologia - L'Hospitalet

L'Hospitalet de Llobregat, Catalunya [cataluña], Spain

Site Status

Hospital Universitario Donostia

Donostia / San Sebastian, Gipuzkoa, Spain

Site Status

Hospital Universitario Arnau de Vilanova de Lleida

Lleida, Lleida [lérida], Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, Madrid, Comunidad de, Spain

Site Status

Hospital Universitario Virgen de la Victoria

Málaga, Málaga, Spain

Site Status

Salut Sant Joan de Reus-Baix Camp (Edp)

Reus, Tarragona [tarragona], Spain

Site Status

Hospital Universitario Virgen Nieves

Granada, , Spain

Site Status

Hospital Universitario San Cecilio

Granada, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

Hospital Universitario HM Sanchinarro

Madrid, , Spain

Site Status

Althaia, Xarxa Assistencial Universitària de Manresa

Manresa, , Spain

Site Status

Hospital Universitario Virgen Macarena

Seville, , Spain

Site Status

Hospital General Universitario de Valencia

Valencia, , Spain

Site Status

Södersjukhuset

Stockholm, Stockholms LÄN [se-01], Sweden

Site Status

Tumor Zentrum Aarau

Aarau, Canton of Aargau, Switzerland

Site Status

Kantonsspital Frauenfeld - Spital Thurgau AG

Frauenfeld, Thurgau, Switzerland

Site Status

Kantonsspital Münsterlingen - Spital Thurgau AG

Münsterlingen, Thurgau, Switzerland

Site Status

Chang Gung Memorial Hospital at Kaohsiung

Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

Site Status

Chi Mei Medical Center

Tainan City, Tainan, Taiwan

Site Status

Chi Mei Hospital - Liouying Branch

Tainan City, Tainan, Taiwan

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan City, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

Mackay Memorial Hospital

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Koo Foundation Sun Yat-Sen Cancer Center

Taipei, , Taiwan

Site Status

Taipei Municipal Wan Fang Hospital

Taipei, , Taiwan

Site Status

Chang Gung Medical Foundation-Linkou Branch

Taoyuan District, , Taiwan

Site Status

Hacettepe Universite Hastaneleri

Altindağ, Ankara, Turkey (Türkiye)

Site Status

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi

Istanbul, İ̇stanbul, Turkey (Türkiye)

Site Status

Acibadem Altunizade Hospital

Istanbul, İ̇stanbul, Turkey (Türkiye)

Site Status

I.E.U. Medical Point Hastanesi

Izmir, İ̇zmir, Turkey (Türkiye)

Site Status

Adana Medical Park Seyhan Hastanesi

Adana, , Turkey (Türkiye)

Site Status

Adana Sehir Egitim ve Arastirma Hastanesi

Adana, , Turkey (Türkiye)

Site Status

Gulhane Egitim Arastirma Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Memorial Ankara Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Ankara Bilkent Şehir Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Akdeniz Universitesi Hastanesi

Antalya, , Turkey (Türkiye)

Site Status

Trakya University Medical Faculty Hospital

Edirne, , Turkey (Türkiye)

Site Status

Samsun Medical Park Hastanesi

Samsun, , Turkey (Türkiye)

Site Status

St Bartholomew's Hospital

London, London, CITY of, United Kingdom

Site Status

Royal Blackburn Hospital

Blackburn, , United Kingdom

Site Status

The Beatson West of Scotland Cancer Centre

Glasgow, , United Kingdom

Site Status

The Christie Hospital NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Belgium Brazil Bulgaria Canada China Czechia Finland France Germany Greece Hungary India Israel Italy Japan Mexico Poland Puerto Rico Slovakia South Africa South Korea Spain Sweden Switzerland Taiwan Turkey (Türkiye) United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP; VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025 Aug 7;393(6):556-568. doi: 10.1056/NEJMoa2505725. Epub 2025 May 31.

Reference Type DERIVED
PMID: 40454645 (View on PubMed)

Hamilton EP, Ma C, De Laurentiis M, Iwata H, Hurvitz SA, Wander SA, Danso M, Lu DR, Perkins Smith J, Liu Y, Tran L, Anderson S, Campone M. VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer. Future Oncol. 2024;20(32):2447-2455. doi: 10.1080/14796694.2024.2377530. Epub 2024 Jul 29.

Reference Type DERIVED
PMID: 39072356 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://pmiform.com/clinical-trial-info-request?StudyID=C4891001

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022-500544-38-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

C4891001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study of PF-06873600 in People With Cancer
NCT03519178 TERMINATED PHASE1/PHASE2
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252 RECRUITING PHASE1/PHASE2